# OnCo record lb2102 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lb2102/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lb2102" ;
  schema:name "LB2102"@en ;
  schema:description "LB2102 is an experimental CAR-T cell therapy for small cell lung cancer, made from a patient's own immune cells and aimed at the protein DLL3. Legend Biotech licensed it to Novartis in November 2023."@en ;
  schema:url <https://onco.cc/drugs/lb2102/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.outsourcedpharma.com/doc/legend-biotech-announces-exclusive-global-license-agreement-for-certain-car-t-therapies-targeting-dll-0001>, <https://clinicaltrials.gov/study/NCT05680922> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Autologous CAR-T cell therapy (DLL3)" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/dll3/> ;
  onco:companies <https://onco.cc/companies/legend-biotech/>, <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/nct05680922/> .